Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Robertson

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 1, 1993
Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brainD T Wong, F P Bymaster, L R Reid, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1988
Metabolism of the prodrug DEGA (N-(2,6-dimethylphenyl)-4-[[(diethylamino)acetyl]amino]benzamide) to the potent anticonvulsant LY201116 in mice. Effect of bis-(p-nitrophenyl)phosphateC J Parli, E Evenson, B D Potts, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
DOI and alpha-methylserotonin: comparative vascular and nonvascular smooth muscle effects and central 5-hydroxytryptamine2 receptor affinitiesM L Cohen, M P Johnson, K W Schenck, et al.
Journal of Medicinal Chemistry|October 1, 1987
Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-dimethylbenzamideD W Robertson, J D Leander, R Lawson, et al.
Journal of Medicinal Chemistry|June 1, 1985
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridineD W Robertson, E E Beedle, J H Krushinski, et al.
British Journal of Pharmacology|February 1, 1992
Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligandsJ M Barnes, N M Barnes, B Costall, et al.
Journal of Medicinal Chemistry|April 1, 1991
Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsantD W Robertson, E E Beedle, J H Krushinski, et al.
Journal of Medicinal Chemistry|October 1, 1986
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- oneD W Robertson, J H Krushinski, E E Beedle, et al.
Brain Research|July 9, 1993
Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdalaA Abi-Dargham, M Laruelle, B Lipska, et al.
Journal of Medicinal Chemistry|May 1, 1986
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinoneD W Robertson, E E Beedle, J K Swartzendruber, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 1, 1993
Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brainD T Wong, F P Bymaster, L R Reid, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1988
Metabolism of the prodrug DEGA (N-(2,6-dimethylphenyl)-4-[[(diethylamino)acetyl]amino]benzamide) to the potent anticonvulsant LY201116 in mice. Effect of bis-(p-nitrophenyl)phosphateC J Parli, E Evenson, B D Potts, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
DOI and alpha-methylserotonin: comparative vascular and nonvascular smooth muscle effects and central 5-hydroxytryptamine2 receptor affinitiesM L Cohen, M P Johnson, K W Schenck, et al.
Journal of Medicinal Chemistry|October 1, 1987
Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-dimethylbenzamideD W Robertson, J D Leander, R Lawson, et al.
Journal of Medicinal Chemistry|June 1, 1985
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridineD W Robertson, E E Beedle, J H Krushinski, et al.
British Journal of Pharmacology|February 1, 1992
Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligandsJ M Barnes, N M Barnes, B Costall, et al.
Journal of Medicinal Chemistry|April 1, 1991
Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsantD W Robertson, E E Beedle, J H Krushinski, et al.
Journal of Medicinal Chemistry|October 1, 1986
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- oneD W Robertson, J H Krushinski, E E Beedle, et al.
Brain Research|July 9, 1993
Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdalaA Abi-Dargham, M Laruelle, B Lipska, et al.
Journal of Medicinal Chemistry|May 1, 1986
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinoneD W Robertson, E E Beedle, J K Swartzendruber, et al.
Pageof 9